XRAY Director Acquires 2,638 Phantom Stock Shares on Dec 31

Insider trading signals often reveal what company leaders truly believe about their business. When executives acquire shares, it sends a powerful message to the market. Today we examine a significant insider transaction at XRAY (DENTSPLY SIRONA Inc.), where a director acquired phantom stock through the company’s deferred compensation plan. This insider transaction occurred on December 31, 2026, and was filed with the SEC on January 2, 2026. The acquisition adds another layer to understanding executive confidence in the dental equipment manufacturer.

Director Acquires Phantom Stock Through Deferred Compensation

Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA, acquired 2,638 shares of phantom stock on December 31, 2026. This transaction represents an award under the company’s Directors’ Deferred Compensation (DDC) plan. Phantom stock is a form of compensation that tracks the value of actual company shares without granting voting rights. The award increased Mazelsky’s total phantom stock holdings to 14,382 shares. This type of insider transaction is common among board members and reflects the company’s compensation structure for directors.

Understanding Phantom Stock Awards

Phantom stock awards serve as deferred compensation for directors and executives. Unlike regular stock, phantom shares don’t grant voting rights or ownership stakes. Instead, they provide cash payments equal to the share value at a future date. DENTSPLY SIRONA uses this mechanism to align director interests with shareholder value. The award structure encourages long-term commitment from board members. Directors benefit when the company performs well, creating incentive alignment.

SEC Filing Details and Transaction Classification

The SEC filing was submitted on January 2, 2026, documenting the December 31 transaction. The form type is a Form 4, which reports changes in insider ownership. The transaction code “A-Award” indicates this was a grant or award of securities. No purchase price was involved since phantom stock is granted as compensation. The filing shows Mazelsky’s complete holdings after the transaction. This transparency requirement helps investors track insider activity at public companies.

What Form 4 Filings Reveal

Form 4 filings are mandatory disclosures for officers, directors, and major shareholders. They must be filed within two business days of the transaction. These filings provide critical transparency into insider activity. Investors use Form 4 data to gauge executive confidence and market sentiment. The filings include transaction details, pricing, and updated ownership positions. DENTSPLY SIRONA’s filing demonstrates compliance with SEC regulations.

Insider Activity Signal and Market Implications

This insider transaction represents a buying signal, though with important context. Mazelsky’s acquisition of phantom stock through an award differs from open-market purchases. The director didn’t spend personal capital to acquire these shares. Instead, the company granted them as part of his compensation package. However, the award still reflects the company’s confidence in future performance. Directors typically accept deferred compensation when they believe the company will grow. This transaction adds to the overall picture of insider sentiment at DENTSPLY SIRONA.

Analyzing Director Confidence

Director acquisitions, even through compensation awards, suggest positive outlook. Mazelsky’s increased holdings demonstrate commitment to the company’s future. The phantom stock structure ties his compensation to shareholder returns. When directors accept deferred compensation, they’re betting on long-term value creation. This transaction, combined with other insider activity, helps investors assess management confidence. DENTSPLY SIRONA’s board appears aligned with shareholder interests through this compensation approach.

DENTSPLY SIRONA Market Position and Meyka Grade

DENTSPLY SIRONA operates in the dental equipment and supplies sector with a market cap of $2.2 billion. The company serves dental professionals globally with innovative products and solutions. Meyka AI rates XRAY with a grade of B, reflecting solid fundamentals and sector performance. This grade factors in financial growth, key metrics, and analyst consensus. The company’s insider activity provides additional context for investors evaluating the stock. Understanding insider transactions helps complete the investment picture alongside Meyka’s proprietary analysis.

Why Insider Transactions Matter

Insider transactions offer real-time signals about executive confidence. They reveal what company leaders believe about future prospects. When insiders acquire shares, it often precedes positive developments. Conversely, insider sales can signal caution or portfolio rebalancing. DENTSPLY SIRONA’s director acquisition through phantom stock shows commitment. Investors should monitor insider activity as one factor among many in their research.

Final Thoughts

Jonathan Mazelsky’s acquisition of 2,638 phantom stock shares through DENTSPLY SIRONA’s deferred compensation plan signals director confidence in the company’s future. While this award differs from open-market purchases, it demonstrates the board’s alignment with shareholder interests. The transaction increases Mazelsky’s total holdings to 14,382 phantom shares, reflecting his ongoing commitment to the company. For investors tracking insider activity at XRAY, this filing provides transparency into executive compensation and confidence levels. Combined with Meyka AI’s B grade for DENTSPLY SIRONA, insider transactions help paint a complete picture of the company’s prospects and leadership s…

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.